Efficacy of adjuvant chemotherapy in stage II colon cancer patients with twelve or more lymph nodes retrieve.

IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Yu Huo, Yue-Yang Zhang, Shuai Jiao, Zhong-Yuan Bai, Wen-Qi Bai, Hai-Tao Zhou, Xu Guan
{"title":"Efficacy of adjuvant chemotherapy in stage II colon cancer patients with twelve or more lymph nodes retrieve.","authors":"Yu Huo, Yue-Yang Zhang, Shuai Jiao, Zhong-Yuan Bai, Wen-Qi Bai, Hai-Tao Zhou, Xu Guan","doi":"10.4251/wjgo.v17.i9.108470","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The National Comprehensive Cancer Network guidelines recommend adjuvant chemotherapy (ACT) for patients with stage II colon cancer who have undergone curative surgery when fewer than 12 lymph nodes (LNs) are retrieved. This study seeks to further examine the requirement for ACT in individuals who had 12 or more LNs harvested.</p><p><strong>Aim: </strong>To investigate if stage II colon cancer patients with 12 or more LNs retrieved benefit from ACT.</p><p><strong>Methods: </strong>This retrospective cohort study included individuals diagnosed with stage II colon cancer who underwent surgery between 2008 and 2017 from the Surveillance, Epidemiology, and End Results (SEER) registry and a Chinese multicenter database. All patients had at least 12 LNs retrieved. The key endpoint was overall survival (OS). Cox regression analysis was performed to assess independent OS predictors. Propensity score matching controlled for confounders, and Kaplan-Meier analysis evaluated the impact of ACT on survival.</p><p><strong>Results: </strong>A total of 32742 patients with stage II colon cancer from the SEER cohort and 3153 patients from the Chinese cohort were included. The average number of LNs retrieved was 20.0 (15.0, 26.0) in the SEER cohort and 18.0 (15.0, 22.0) in the Chinese cohort. No-ACT remained an independent risk factor in both cohorts (hazard ratio = 1.589, 95% confidence interval: 1.485-1.700 and hazard ratio = 1.865, 95% confidence interval: 1.465-2.375, respectively). In the SEER cohort, patients in the ACT group consistently demonstrated better 5-year OS rates both before and after propensity score matching (79.4% <i>vs</i> 66.1% and 79.4% <i>vs</i> 69.4%, both <i>P</i> < 0.0001). Similarly, these findings were further validated in the Chinese cohort (91.2% <i>vs</i> 82.1% and 90.0% <i>vs</i> 82.8%, both <i>P</i> < 0.0001). ACT improved prognosis even in T3 and grade 1/2 patients.</p><p><strong>Conclusion: </strong>This research, based on two large population-based cohorts, demonstrates that stage II colon cancer patients with 12 or more LNs retrieved can still benefit from ACT.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 9","pages":"108470"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444335/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4251/wjgo.v17.i9.108470","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The National Comprehensive Cancer Network guidelines recommend adjuvant chemotherapy (ACT) for patients with stage II colon cancer who have undergone curative surgery when fewer than 12 lymph nodes (LNs) are retrieved. This study seeks to further examine the requirement for ACT in individuals who had 12 or more LNs harvested.

Aim: To investigate if stage II colon cancer patients with 12 or more LNs retrieved benefit from ACT.

Methods: This retrospective cohort study included individuals diagnosed with stage II colon cancer who underwent surgery between 2008 and 2017 from the Surveillance, Epidemiology, and End Results (SEER) registry and a Chinese multicenter database. All patients had at least 12 LNs retrieved. The key endpoint was overall survival (OS). Cox regression analysis was performed to assess independent OS predictors. Propensity score matching controlled for confounders, and Kaplan-Meier analysis evaluated the impact of ACT on survival.

Results: A total of 32742 patients with stage II colon cancer from the SEER cohort and 3153 patients from the Chinese cohort were included. The average number of LNs retrieved was 20.0 (15.0, 26.0) in the SEER cohort and 18.0 (15.0, 22.0) in the Chinese cohort. No-ACT remained an independent risk factor in both cohorts (hazard ratio = 1.589, 95% confidence interval: 1.485-1.700 and hazard ratio = 1.865, 95% confidence interval: 1.465-2.375, respectively). In the SEER cohort, patients in the ACT group consistently demonstrated better 5-year OS rates both before and after propensity score matching (79.4% vs 66.1% and 79.4% vs 69.4%, both P < 0.0001). Similarly, these findings were further validated in the Chinese cohort (91.2% vs 82.1% and 90.0% vs 82.8%, both P < 0.0001). ACT improved prognosis even in T3 and grade 1/2 patients.

Conclusion: This research, based on two large population-based cohorts, demonstrates that stage II colon cancer patients with 12 or more LNs retrieved can still benefit from ACT.

Abstract Image

Abstract Image

Abstract Image

辅助化疗在12个或更多淋巴结恢复的II期结肠癌患者中的疗效。
背景:国家综合癌症网络指南推荐辅助化疗(ACT)用于II期结肠癌患者,当切除的淋巴结少于12个时,他们已经接受了治愈性手术。本研究旨在进一步研究切除12个或更多ln的个体对ACT的需求。目的:探讨有12个或更多ln的II期结肠癌患者是否能从ACT中获益。方法:这项回顾性队列研究纳入了2008年至2017年间接受手术的II期结肠癌患者,这些患者来自监测、流行病学和最终结果(SEER)登记和中国多中心数据库。所有患者至少有12个ln被取出。主要终点是总生存期(OS)。采用Cox回归分析评估独立OS预测因子。倾向评分匹配控制混杂因素,Kaplan-Meier分析评估ACT对生存的影响。结果:共纳入来自SEER队列的32742例II期结肠癌患者和来自中国队列的3153例患者。平均检索到的LNs数在SEER组为20.0(15.0,26.0),在中国组为18.0(15.0,22.0)。在两个队列中,No-ACT仍然是独立的危险因素(风险比分别为1.589,95%可信区间为1.485-1.700;风险比分别为1.865,95%可信区间为1.465-2.375)。在SEER队列中,ACT组患者在倾向评分匹配前后均表现出更好的5年OS率(79.4% vs 66.1%, 79.4% vs 69.4%, P均< 0.0001)。同样,这些发现在中国队列中得到进一步验证(91.2% vs 82.1%, 90.0% vs 82.8%, P均< 0.0001)。ACT改善了T3和1/2级患者的预后。结论:这项基于两个大型人群队列的研究表明,获得12个或更多ln的II期结肠癌患者仍然可以从ACT中获益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World Journal of Gastrointestinal Oncology
World Journal of Gastrointestinal Oncology Medicine-Gastroenterology
CiteScore
4.20
自引率
3.30%
发文量
1082
期刊介绍: The World Journal of Gastrointestinal Oncology (WJGO) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信